Anti-YSK4 monoclonal antibody

Pre-made anti-YSK4 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to YSK4/MAP3K19 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T42157-Ab-1/ GM-Tg-hg-T42157-Ab-2Anti-Human YSK4/MAP3K19 monoclonal antibodyHuman
GM-Tg-rg-T42157-Ab-1/ GM-Tg-rg-T42157-Ab-2Anti-Rat YSK4/MAP3K19 monoclonal antibodyRat
GM-Tg-mg-T42157-Ab-1/ GM-Tg-mg-T42157-Ab-2Anti-Mouse YSK4/MAP3K19 monoclonal antibodyMouse
GM-Tg-cynog-T42157-Ab-1/ GM-Tg-cynog-T42157-Ab-2Anti-Cynomolgus/ Rhesus macaque YSK4/MAP3K19 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T42157-Ab-1/ GM-Tg-felg-T42157-Ab-2Anti-Feline YSK4/MAP3K19 monoclonal antibodyFeline
GM-Tg-cang-T42157-Ab-1/ GM-Tg-cang-T42157-Ab-2Anti-Canine YSK4/MAP3K19 monoclonal antibodyCanine
GM-Tg-bovg-T42157-Ab-1/ GM-Tg-bovg-T42157-Ab-2Anti-Bovine YSK4/MAP3K19 monoclonal antibodyBovine
GM-Tg-equg-T42157-Ab-1/ GM-Tg-equg-T42157-Ab-2Anti-Equine YSK4/MAP3K19 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T42157-Ab-1/ GM-Tg-hg-T42157-Ab-2; GM-Tg-rg-T42157-Ab-1/ GM-Tg-rg-T42157-Ab-2;
GM-Tg-mg-T42157-Ab-1/ GM-Tg-mg-T42157-Ab-2; GM-Tg-cynog-T42157-Ab-1/ GM-Tg-cynog-T42157-Ab-2;
GM-Tg-felg-T42157-Ab-1/ GM-Tg-felg-T42157-Ab-2; GM-Tg-cang-T42157-Ab-1/ GM-Tg-cang-T42157-Ab-2;
GM-Tg-bovg-T42157-Ab-1/ GM-Tg-bovg-T42157-Ab-2; GM-Tg-equg-T42157-Ab-1/ GM-Tg-equg-T42157-Ab-2
Products NameAnti-YSK4/MAP3K19 monoclonal antibody
Formatmab
Target NameYSK4
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-YSK4 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T42157-Ag-1Recombinant multi-species M3K19/ YSK4/ MAP3K19 protein


    Target information

    Target IDGM-T42157
    Target NameYSK4
    Gene ID80122,22625,289001,712728,483897,101090454,538897,100050587
    Gene Symbol and SynonymsAABR07020879.1,MAP3K19,RCK,RGD1566400,YSK4
    Uniprot AccessionQ56UN5
    Uniprot Entry NameM3K19_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000176601
    Target ClassificationKinase

    The target: YSK4, gene name: MAP3K19, also named as RCK, YSK4. Predicted to enable ATP binding activity; protein serine kinase activity; and protein serine/threonine kinase activity. Predicted to be involved in protein phosphorylation. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.